Merck’s two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint
Merck today reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients …
My Glucose Screening- Checking for Gestational Diabetes In Pregnancy